DE69920208T2 - Verbindungen, die als reversible inhibitoren der carnitin palmitoyltransferase wirsam sind - Google Patents

Verbindungen, die als reversible inhibitoren der carnitin palmitoyltransferase wirsam sind Download PDF

Info

Publication number
DE69920208T2
DE69920208T2 DE69920208T DE69920208T DE69920208T2 DE 69920208 T2 DE69920208 T2 DE 69920208T2 DE 69920208 T DE69920208 T DE 69920208T DE 69920208 T DE69920208 T DE 69920208T DE 69920208 T2 DE69920208 T2 DE 69920208T2
Authority
DE
Germany
Prior art keywords
group
trimethylammonium
aminobutyrate
compounds
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69920208T
Other languages
German (de)
English (en)
Other versions
DE69920208D1 (de
Inventor
Fabio Giannessi
Mauro Marzi
Patrizia Minetti
Francesco De Angelis
Ornella Maria TINTI
Piero Chiodi
Arduino Arduini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Application granted granted Critical
Publication of DE69920208D1 publication Critical patent/DE69920208D1/de
Publication of DE69920208T2 publication Critical patent/DE69920208T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/06—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms
    • C07C335/08—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5407—Acyclic saturated phosphonium compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
DE69920208T 1998-05-15 1999-05-11 Verbindungen, die als reversible inhibitoren der carnitin palmitoyltransferase wirsam sind Expired - Lifetime DE69920208T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI981075 1998-05-15
IT98MI001075A IT1299266B1 (it) 1998-05-15 1998-05-15 Inibitori reversibili della carnitina palmitoil trasferasi
PCT/IT1999/000126 WO1999059957A1 (en) 1998-05-15 1999-05-11 Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase

Publications (2)

Publication Number Publication Date
DE69920208D1 DE69920208D1 (de) 2004-10-21
DE69920208T2 true DE69920208T2 (de) 2005-10-20

Family

ID=11380036

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69920208T Expired - Lifetime DE69920208T2 (de) 1998-05-15 1999-05-11 Verbindungen, die als reversible inhibitoren der carnitin palmitoyltransferase wirsam sind
DE69942315T Expired - Lifetime DE69942315D1 (de) 1998-05-15 1999-05-11 Verbindungen, die als reversible Inhibitoren der Carnitin Palmitoyltransferase wirksam sind

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69942315T Expired - Lifetime DE69942315D1 (de) 1998-05-15 1999-05-11 Verbindungen, die als reversible Inhibitoren der Carnitin Palmitoyltransferase wirksam sind

Country Status (14)

Country Link
US (4) US6369073B1 (OSRAM)
EP (2) EP1077925B1 (OSRAM)
JP (1) JP5127093B2 (OSRAM)
KR (1) KR100585443B1 (OSRAM)
AT (2) ATE465988T1 (OSRAM)
AU (1) AU3847399A (OSRAM)
CA (1) CA2329930C (OSRAM)
CY (1) CY1110200T1 (OSRAM)
DE (2) DE69920208T2 (OSRAM)
DK (2) DK1077925T3 (OSRAM)
ES (2) ES2345100T3 (OSRAM)
IT (1) IT1299266B1 (OSRAM)
PT (2) PT1484313E (OSRAM)
WO (1) WO1999059957A1 (OSRAM)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1299266B1 (it) 1998-05-15 2000-02-29 Sigma Tau Ind Farmaceuti Inibitori reversibili della carnitina palmitoil trasferasi
US6822115B2 (en) * 1999-06-30 2004-11-23 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Synthesis of (R) and (S)-aminocarnitine, (R) and (S)-4-phosphonium-3-amino-butanoate, (R) and (S) 3,4-diaminobutanoic acid, and their derivatives starting from D- and L-aspartic acid
IT1317885B1 (it) * 2000-08-01 2003-07-15 Sigma Tau Ind Farmaceuti Uso di fibrati per la preparazione di un medicamento utile neltrattamento dell'insufficienza cardiaca congestizia.
ITRM20010456A1 (it) * 2001-07-26 2003-01-27 Sigma Tau Ind Farmaceuti Procedimento per la preparazione di (r)- o (s)- amminocarnitina sale interno, dei suoi sali e dei suoi derivati.
US7045547B2 (en) * 2002-08-20 2006-05-16 University Of Delaware Acyl-CoA dehydrogenase allenic inhibitors
ITRM20030053A1 (it) * 2003-02-10 2004-08-11 Sigma Tau Ind Farmaceuti Associazione di farmaci antidiabetici.
EP1594439A2 (en) * 2003-02-13 2005-11-16 Albert Einstein College Of Medicine Of Yeshiva University REGULATION OF FOOD INTAKE AND GLUCOSE PRODUCTION BY MODULATION OF LONG-CHAIN FATTY ACYL-CoA LEVELS IN THE HYPOTHALAMUS
US7041286B2 (en) * 2003-07-23 2006-05-09 Nerenberg Arnold P Composition for mitigating a pernicious thrombotic event
US8314144B2 (en) 2004-02-12 2012-11-20 Defiante Farmaceutica, S.A. Compounds having antitumor activity
ITMI20040230A1 (it) * 2004-02-12 2004-05-12 Defiante Farmaceutica Lda Composti ad attivita' antitumorale
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
US20070026079A1 (en) * 2005-02-14 2007-02-01 Louis Herlands Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels
ITRM20050090A1 (it) * 2005-03-02 2006-09-03 Sigma Tau Ind Farmaceutiche Riunite Spa Derivati dell'acido ammino-butanoico inibitore della cpt.
MX2007014927A (es) * 2005-06-06 2008-02-15 Hoffmann La Roche Derivados de sulfonamida utiles como inhibidores de palmitoil transferasa de carnitina de higado.
KR20090034969A (ko) * 2006-08-02 2009-04-08 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. 씨피티-억제제로서 4-트라이메틸암모늄-3-아미노부티레이트및 4-트라이메틸포스포늄-3-아미노부티레이트의 유도체
US8410150B2 (en) 2007-03-09 2013-04-02 University Health Network Inhibitors of carnitine palmitoyltransferase and treating cancer
US20100210695A1 (en) * 2007-06-22 2010-08-19 Dara Biosciences, Inc. Compositions and methods for treating skin disorders
CA2677049A1 (en) 2007-08-01 2009-02-05 Sionex Corporation Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer
WO2009019199A1 (en) * 2007-08-07 2009-02-12 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Crystalline teglicar
US20100064413A1 (en) * 2008-03-14 2010-03-18 Simply Weights, LLC Exercise clothing and accessories
KR101225223B1 (ko) 2008-04-29 2013-01-22 에프. 호프만-라 로슈 아게 4-다이메틸아미노부티르산 유도체
RU2502727C2 (ru) * 2008-04-29 2013-12-27 Ф.Хоффманн-Ля Рош Аг 4-триметиламмониобутираты в качестве ингибиторов срт2
CN102159080A (zh) * 2008-06-24 2011-08-17 达拉生物科学公司 酶抑制剂及其用途
CA2733390A1 (en) * 2008-08-01 2010-02-04 Bioxiness Pharmaceuticals, Inc. Methionine analogs and methods of using same
EP2348865B1 (en) 2008-10-08 2015-07-15 Nucitec S.A. de C.V. Beta-hydroxy-gamma-aminophosphonates and methods for the preparation and use thereof
WO2011017335A1 (en) 2009-08-03 2011-02-10 Incube Labs, Llc Swallowable capsule and method for stimulating incretin production within the intestinal tract
US8721620B2 (en) 2009-12-24 2014-05-13 Rani Therapeutics, Llc Swallowable drug delivery device and methods of drug delivery
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9283179B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9259386B2 (en) 2010-12-23 2016-02-16 Rani Therapeutics, Llc Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9861683B2 (en) 2010-12-23 2018-01-09 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9284367B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10639272B2 (en) 2010-12-23 2020-05-05 Rani Therapeutics, Llc Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US9402806B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809271B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising liraglutide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9629799B2 (en) 2010-12-23 2017-04-25 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8846040B2 (en) 2010-12-23 2014-09-30 Rani Therapeutics, Llc Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9415004B2 (en) 2010-12-23 2016-08-16 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8734429B2 (en) 2010-12-23 2014-05-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US8980822B2 (en) 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402807B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809269B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9492466B2 (en) 2012-06-14 2016-11-15 Nucitec S.A. De C.V. Beta-hydroxy-gamma-aminophosphonates for treating immune disorders
JP6473352B2 (ja) * 2015-03-10 2019-02-20 利幸 糸井 虚血性疾患治療薬
AU2020339557A1 (en) 2019-08-30 2022-03-24 Institute Of Zoology, Chinese Academy Of Sciences Composition used for combating metabolic diseases and uses of composition

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3810994A (en) * 1972-06-01 1974-05-14 Ethyl Corp Method and composition for treating obesity
JPS59216857A (ja) 1983-05-25 1984-12-06 Takeda Chem Ind Ltd Ｆａ―５８５９関連化合物
CH655005A5 (it) * 1983-02-16 1986-03-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.
EP0127098B1 (en) 1983-05-25 1989-02-08 Takeda Chemical Industries, Ltd. Derivatives of beta-amino-gamma-trimethylammonio-butyrate, their production and use
EP0177574B1 (en) * 1984-04-02 1989-12-20 Cornell Research Foundation, Inc. Aminocarnitines
IT1190163B (it) * 1986-01-13 1988-02-16 Sigma Tau Ind Farmaceuti Derivati fosforilalcanolammidici della l-carnitina e composizioni farmaceutiche che li contengono
US5196418A (en) * 1992-02-14 1993-03-23 Board Of Supervisors, Louisiana State University Agricultural & Mechanical College Hemicholinium lipids and use thereof
HUT65327A (en) * 1992-06-11 1994-05-02 Sandoz Ag Process for producing phosphinyloxy-propyl-ammonium inner sact derwatives ang pharmateutical preparations containing them
AU4534593A (en) * 1992-06-12 1994-01-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
IT1263004B (it) * 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
WO1998000389A1 (en) * 1996-07-02 1998-01-08 Sang Sup Jew 2-hydroxypropionic acid derivative and its manufacturing method
IT1299266B1 (it) 1998-05-15 2000-02-29 Sigma Tau Ind Farmaceuti Inibitori reversibili della carnitina palmitoil trasferasi
US6822115B2 (en) * 1999-06-30 2004-11-23 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Synthesis of (R) and (S)-aminocarnitine, (R) and (S)-4-phosphonium-3-amino-butanoate, (R) and (S) 3,4-diaminobutanoic acid, and their derivatives starting from D- and L-aspartic acid
IT1306162B1 (it) * 1999-06-30 2001-05-30 Sigma Tau Ind Farmaceuti Sintesi di (r) e (s)-amminocarnitina e di suoi derivati a partire daacido d e l-aspartico.
ITRM20010456A1 (it) * 2001-07-26 2003-01-27 Sigma Tau Ind Farmaceuti Procedimento per la preparazione di (r)- o (s)- amminocarnitina sale interno, dei suoi sali e dei suoi derivati.

Also Published As

Publication number Publication date
DK1077925T3 (da) 2005-01-24
ES2345100T3 (es) 2010-09-15
US6444701B1 (en) 2002-09-03
EP1484313B1 (en) 2010-04-28
PT1484313E (pt) 2010-07-21
CY1110200T1 (el) 2015-01-14
JP5127093B2 (ja) 2013-01-23
EP1077925B1 (en) 2004-09-15
EP1484313A1 (en) 2004-12-08
DE69920208D1 (de) 2004-10-21
USRE41226E1 (en) 2010-04-13
AU3847399A (en) 1999-12-06
USRE40861E1 (en) 2009-07-21
KR100585443B1 (ko) 2006-06-02
US6369073B1 (en) 2002-04-09
US20020052348A1 (en) 2002-05-02
DE69942315D1 (de) 2010-06-10
HK1033573A1 (en) 2001-09-07
CA2329930C (en) 2010-02-23
KR20010034862A (ko) 2001-04-25
IT1299266B1 (it) 2000-02-29
ATE276230T1 (de) 2004-10-15
ATE465988T1 (de) 2010-05-15
PT1077925E (pt) 2004-12-31
ITMI981075A1 (it) 1999-11-15
ES2230854T3 (es) 2005-05-01
CA2329930A1 (en) 1999-11-25
DK1484313T3 (da) 2010-07-19
WO1999059957A1 (en) 1999-11-25
JP2003513002A (ja) 2003-04-08
WO1999059957A9 (en) 2002-06-13
EP1077925A1 (en) 2001-02-28

Similar Documents

Publication Publication Date Title
DE69920208T2 (de) Verbindungen, die als reversible inhibitoren der carnitin palmitoyltransferase wirsam sind
DE69409525T2 (de) Acetamidderivate und ihre verwendung als modifizierungsmittel des verhaltens der verdauung
DE2446010C2 (de) 4-(Monoalkylamino)benzoesäurederivate und sie enthaltende therapeutische Zubereitung
DE2607620C2 (de) 4-Amino-5-hexensäure und Verfahren zu deren Herstellung
DE69735634T2 (de) Substituierte cyclopentanderivate die als neuramidase-inhibitoren nuetzlich sind
EP0600949A1 (de) Neue 3,5-di-tert.butyl-4-hydroxyphenyl-derivate, verfahren zu ihrer herstellung und arzneimittel.
CH630604A5 (de) Verfahren zur herstellung von neuen acetylenderivaten von aminosaeuren.
EP0381070A1 (en) Synthetic amphiphilic glycoconjugates for neurological use
EP0374095A2 (de) Piperidinderivate
DE3229893A1 (de) Neue aminosaeureisomere, verfahren zu ihrer herstellung sowie ihre verwendung
DE69107217T2 (de) Oxysulfonylharnstoff-acat-inhibitoren.
DE2701854A1 (de) Hypolipidaemische p-benzylaminobenzoesaeuren und sie enthaltende mittel
DE3872213T2 (de) 5-substituierte ornithin-derivate.
DE3424107C2 (OSRAM)
DE69208464T2 (de) N-((4,5-dihydroxy- und 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracen-yl)carbonyl)aminosäure zur therapie osteoartikulärer leiden
DE3883270T2 (de) Substituierte Biphenylderivate.
DE69106386T2 (de) Oxysulfonylcarbamate.
DE69509091T2 (de) Salze von 2-[(2,6-dichlorophenyl)amin]phenylacetoxyessigsäure mit organischen basischen kationen
EP0203450B1 (de) Neue Derivate bicyclischer Aminosäuren, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und deren Verwendung
DE69600780T2 (de) 15-deoxyspergualin-analoge verbindungen, ihre verwendung als therapeutika und verfahren zu ihrer herstellung
DE69909486T2 (de) Phenylester-derivate von alpha-aminosäuren
DE3023433A1 (de) Acylaminobenzoesaeurederivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
DE3037391A1 (de) Ester von 7-hydroxyalkyl-1,3-dimethylxanthinen, verfahren zu ihrer herstellung und ihre verwendung als lipidsenkende mittel
HK1033573B (en) Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase
EP0154886A2 (de) Carboxyalkyldipeptidderivate, Verfahren zu deren Herstellung, diese enthaltende Mittel und deren Verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition